People

Lila Brown is executive assistant with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Gretchen Piller is managing director with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Leslie Lake is managing director with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Jayme Samuel is executive assistant with Invus Opportunities, Invus Financial Advisors Team, based in New York. Invus Opportunities invests in private technology businesses.

Rachel Merluza is director of finance & compliance with Invus Opportunities, Invus Financial Advisors Team. The published role covers Global. Invus Opportunities invests in private technology businesses.

Carmen Taton is chief financial officer with Invus Opportunities, Invus Financial Advisors Team. The published role covers Global. Invus Opportunities invests in private technology businesses.

Sacha Lainovic is managing director with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Leticia Bombieri is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Udai Pal is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Pedro Saltos is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

David Kahane is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Bryan Kim is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Benjamin Tsai is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Cassie Wang is administrative manager with administration, based in Hong Kong. The role supports the firm’s global investment operations.

Jen Xu is financial controller with administration. The published role covers Asia. The role supports the firm’s global investment operations.

Andrea Prieto is executive assistant , public equity with administration, based in Paris. The role supports the firm’s global investment operations.

Adriana Alb is director of administration with administration, based in Paris. The role supports the firm’s global investment operations.

Maxime Szwabinski is vice president of operations , public equity with administration, based in Paris. The role supports the firm’s global investment operations.

Gabryelle Francois is executive assistant , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Judy Wong is executive assistant with administration. The published role covers United States. The role supports the firm’s global investment operations.

Amanda Peso is executive assistant with administration, based in New York. The role supports the firm’s global investment operations.

Nancy Liao is executive assistant , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Sophia Forde is executive assistant , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Michelle Lavoie is office manager with administration. The published role covers United States. The role supports the firm’s global investment operations.

Tanesha Barnett is executive assistant & private equity team coordinator , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Mackenzie Walsh is operations associate , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

John Pratt is senior operations associate , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Vincent Buonomo is controller , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Simona Abikova is global human resources manager with administration, based in New York. The role supports the firm’s global investment operations.

Patrycja Poweska is senior accountant with administration, based in New York. The role supports the firm’s global investment operations.

Cheung Yuet Fan is a joint company secretary of WuXi AppTec. The2025 annual corporate report identifies her as an external service provider from Tricor Services Limited, a Vistra-group member, continuing alongside Min Han. This is an external corporate-secretarial appointment, not an inferred operating-company employment or expanded career biography.

Eleanor Wilson is accounting manager with administration, based in New York. The role supports the firm’s global investment operations.

Kelly Hickey is vice president of finance with administration, based in New York. The role supports the firm’s global investment operations.

Min Han is board secretary and joint company secretary of WuXi AppTec. Appointed joint company secretary July28,2025 and boardsecretary reappointedApril28,2026. Her2025 annual biography describes bank/financial-institution and listed-company governance experience, Shanghai University accounting degree, Nottingham finance/investment masters and CPA qualifications in China and the United Kingdom.

Joan Carroll is tax manager with administration, based in New York. The role supports the firm’s global investment operations.

Thanh Tran is compliance analyst with administration, based in New York. The role supports the firm’s global investment operations.

Xuesong Leng is an independent non-executive director and nomination committee chair of WuXi AppTec, appointedJanuary22,2025. His2025 annual biography describes prior Warburg Pincus and General Atlantic leadership, founding Lupin Capital in2015, a Shanghai Jiao Tong international-industrial-trade bachelors degree and Wharton MBA.

Hunter Lite is compliance associate with administration, based in New York. The role supports the firm’s global investment operations.

Christine Bark is compliance associate with administration, based in New York. The role supports the firm’s global investment operations.

Vanessa Lopera-Madrid is director of compliance with administration, based in New York. The role supports the firm’s global investment operations.

Zhiling Zhan is an independent non-executive director of WuXi AppTec. Her2025 annual biography describes principal-lawyer practice at Shanghai Ryser since2004, earlier Renmin University teaching and legal work at Pestalozzi and Baker & McKenzie, and law degrees from Wuhan, Renmin and the University of Tokyo.

Arshaad Yar is chief information officer with administration, based in New York. The role supports the firm’s global investment operations.

Xin Zhang is an independent non-executive director of WuXi AppTec and a Fudan University accounting professor/department vice chair. His current own university biography explicitly corroborates the WuXi appointment and his Shanghai Jiao Tong bachelors/masters and Queens University finance doctorate. His research covers corporate finance, analysts and international accounting/finance.

Philip Bafundo is Invus’s chief financial officer and chief compliance officer, based in New York. His own primary biography describes prior financial leadership in asset management and accounting before joining Invus. His main-group role is distinct from Carmen Taton’s chief financial officer capacity in the Opportunities and Financial Advisors units.

Wei Yu is lead independent non-executive director of WuXi AppTec, elected lead director effectiveApril28,2026. His2025 annual biography describes more than30years in health management/policy research, Shanghai Chuangqi Health Development Academy leadership, prior research roles at U.S./Chinese universities and health institutions, and Shanghai University of Finance and Economics public-economics leadership. He holds an electrical-automation bachelors degree and Clemson economics masters/doctorate.

David Van Zandt is global general counsel with administration, based in New York. The role supports the firm’s global investment operations.

Christine Shaohua Lu-Wong is an independent non-executive director and audit committee chair of WuXi AppTec. Her2025 annual corporate biography describes senior listed-company CFO/finance roles at WuXi PharmaTech, Pactera, Xueda and WuXi Biologics, U.S. CPA qualification, a Guangdong foreign-trade/economics degree and Golden Gate University accounting MBA. Historical CFO positions are not treated as current executive roles.

Jiahui Liu is associate with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Yibing Wu is a non-executive director of WuXi AppTec. His2025 annual corporate biography describes prior McKinsey senior partnership and Asia-Pacific M&A leadership, Lenovo/Legend leadership, CITIC Private Equity/Goldstone leadership, and Temasek China leadership since joining in2013. He holds a Harvard biochemistry PhD and USTC molecular-biology degree. His historical WuXi Biologics directorship is not asserted current.

Bohan Xue is senior associate with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Xiaomeng Tong is a non-executive director of WuXi AppTec. His2025 annual corporate biography describes Morgan Stanley investment analysis, senior Greater China roles at General Atlantic and Providence Equity, and managing partner at Boyu since2011. He holds a Harvard economics degree.

Salim Salam is director with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Thomas Dargent is an Invus public equity analyst in Paris, focused on biotechnology. Before joining in2024, he worked in healthcare and innovation, including co-founding a software platform addressing medicine shortages. He holds a pharmacy doctorate from Université Grenoble Alpes and studied entrepreneurship at HEC Paris and École Polytechnique.

Etienne Daher is a senior associate on Invus’s Paris public equity team. Before joining in2024, he was a biotechnology equity analyst at Aescap, chief of staff at Sensorion and a healthcare startup manager at Bpifrance. He holds a pharmacy doctorate from Université Grenoble Alpes and a strategy and international business master’s from ESSEC.

Olivier Gueymard is principal with Public Equity, based in Paris. The role supports Invus’s public equity investment activities.

Antoine Barouky is an Invus venture partner working across the public and private healthcare teams. He joined in2023 after building and leading European operations for Alnylam, Shire, Cubist and Forest Laboratories, and earlier held business development leadership at Stallergenes. He studied biotechnology engineering at INSA Lyon and finance at HEC Paris.

Julien Miara is a managing director leading Invus’s public equity team in Europe from Paris. He joined the firm in2010 and became the European team lead in2018. His investment experience includes biotechnology, software, semiconductors and automotive businesses. Earlier he worked in investment banking and consulting; he studied management at EDHEC.

Ryan Storgard is associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Shubham Chatterjee is an associate investing in public companies from Invus’s New York office. Before joining in2024, he worked in healthcare consulting at Boston Consulting Group and completed biotechnology investment and business development internships. He studied chemical and biological engineering at Princeton, bioengineering at the University of Pennsylvania and business at Wharton.

Isaac Sassoon is an associate on Invus’s New York public equity team. He joined in2023 after biopharmaceutical development and commercialization consulting at LifeSci Consulting. He studied economics and pre-medicine at Cornell and biotechnology at the University of Pennsylvania, where he supported cellular immunotherapy research.

Louccas Bou Jaoude is senior associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Dylan Drakes is senior associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Brian Aronson is vice president with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Quentin Langlois is a director on Invus’s public equity team in New York, focused on private biotechnology investing. Before joining in2025, he was a vice president at H.I.G. BioHealth Partners and held business development and strategy roles at Shire, aTyr Pharma and Theravance Biopharma. He studied law at UVSQ and management at HEC Paris.

Sunny Shah is a New York-based Invus director investing in public and private biotechnology companies across development stages and therapeutic areas. He joined Invus in2020 after academic cardiology work at Weill Cornell Medicine and New York Presbyterian Hospital. His medical training includes New York University and a cardiovascular fellowship at Cornell.

Brittany Sacks is a director on Invus’s public equity team in New York. Before joining in2017, she covered biotechnology in equity research at J.P. Morgan and worked in Pfizer business development on acquisitions, collaborations and licensing. She studied applied economics and management at Cornell University.

Nadim Razzouk is principal with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Robert Mikesell is principal with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Elena Devoy is global head of capital formation with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Jonathan Luick is chief operating officer with Public Equity. The published role covers United States, Europe, Asia. The role supports Invus’s public equity investment activities.

Khalil Barrage is managing director with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Sumit Goenka is senior associate with Private Equity. The published role covers Asia. The team works with private companies and their leadership.

Vishal Medida is senior associate with Private Equity. The published role covers Asia. The team works with private companies and their leadership.

Jimmy Wu is director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Veronica Yingying Li is director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Francis Cukierman is managing director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Judith Levy is associate with Private Equity, based in Paris. The team works with private companies and their leadership.

Corentin Le Garo is senior associate with Private Equity, based in Paris. The team works with private companies and their leadership.

Louis Loze is director with Private Equity, based in Paris. The team works with private companies and their leadership.

Victor Doussineau is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Benedetto Staccia is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Mario Kaloustian is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Luc Ta-Ngoc is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Colin Walton is analyst with Private Equity, based in New York. The team works with private companies and their leadership.

Ian Springer is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Vishesh Shah is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Charles Lefkowicz is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Sally Susman is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Honorary Governors group. The foundation lists the outside professional affiliation: Executive Vice President, Policy, External Affairs and Communications, Pfizer Inc. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Robert A. Belfer is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Honorary Governors group. The foundation lists the outside professional affiliation: Chairman Emeritus, Belfer Management LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Arda Sonmez is senior associate with Private Equity, based in New York. The team works with private companies and their leadership.

Justice Sandra Day O'Connor is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Associate Justice, US Supreme Court. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Melvin R. Goodes is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Former Chairman and Chief Executive Officer, Warner-Lambert. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Samantha Speer is senior associate with Private Equity, based in New York. The team works with private companies and their leadership.

Leonard A. Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Chairman Emeritus, The Estée Lauder Companies Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Wendy L. Wilshin is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founder and Principal, WLW Designs. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Jared Smith is director, data strategy and analytics with Private Equity, based in New York. The team works with private companies and their leadership.

Stephen Toma is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Investor and Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

John H. Scully is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Senior Managing Director and Head of Private Wealth Advisory, Nuveen Investments. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Tom Scanlan is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Partner, Spencer Stuart. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Gregory A. Rosica is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Retired Partner, Tax, Ernst & Young, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Phebe Farrow Port is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Senior Vice President, Global Management Strategies, and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Justin Meltzer is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Real Estate Operations, DLA Piper LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Julie Medler is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Retired Managing Director, JPMorgan. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Philip Lovett is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founding Partner, Millennium Partners. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Elise Gelman Lefkowitz is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

David Nielsen is director with Private Equity, based in New York. The team works with private companies and their leadership.

Josh Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Co-Founder and Co-Chair, ADDF Young Professionals Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Mitchell Kaneff is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Chairman and Chief Executive Officer, Arkay. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Michael Dubin is director with Private Equity, based in New York. The team works with private companies and their leadership.

Allan M. Green is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Allan M. Green Esq., LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Stephanie Ginsberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Volunteer, Philanthropist; Founder, BCRF Pink Promises Benefit. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Clare Joyce is a managing director on the Invus private equity team, published with United States and Asia responsibilities. Her current own biography and portrait identify the investment professional; no unreported personal investment or exact appointment day is inferred.

Dave Gerson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Personal Financial Planning Consultant, Retired Tax Partner Ernst & Young, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Gina F. Fochetta is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Executive Director, J.P. Morgan Private Bank; Co-Founder and Co-Chair, ADDF Young Professionals Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Justin Barstein is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Joel Florin is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: President, Micro Essential Laboratory, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Benjamin Felt is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Mitchell D. Eichen is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Former Founder and Chief Executive Officer, Acertus Capital Management; Former Founder and Chief Executive Officer, The MDE Group. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Charlie Lefkowitz Crowley is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Educational Consultant and Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Kristin Rae Cecchi is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Marketing Design Consultant, Cecchi Homes. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Evren Bilimer is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Charles Cangro is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Former Principal, Personal Financial Services, Ernst & Young, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Bal Agrawal is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founder and Chief Executive Officer, LifeWorx, Inc.; Founder and Chief Executive Officer, Prima Chefs, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Aflalo Guimarães is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Christopher Johnson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Chair group. The foundation lists the outside professional affiliation: President, Rackson Companies. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Jonas Fajgenbaum is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Paula Zahn is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Host and Executive Producer, Discovery ID's "On the Case with Paula Zahn," and WNET's "NYC Arts". This is a foundation governance or honorary affiliation, not an assertion of operating employment.

David R. Weinreb is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Chief Executive Officer, Weinreb Ventures. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Philippe Amouyal is managing director with Private Equity, based in Miami. The team works with private companies and their leadership.

Anthony (Nino) Sireci is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Sr. Vice President, Clinical Biomarkers, Laboratories and Diagnostics, Eli Lilly and Company. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Alice Shure is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Founder and Producer, AMICI Productions LLC; Co-Trustee, The Charles Evans Foundation. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Christopher Sobecki is managing director with Private Equity. The published role covers United States. The team works with private companies and their leadership.

Julieann Shanahan is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Creator, Pavilion Living: Architecture, Patronage and Well-Being. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Sharon T. Sager is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Chair, Finance and Audit Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Richard C. Mohs is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Scientific Investment Approval Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Laurence C. Leeds, Jr. is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Former Chairman, Buckingham Capital Management, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Bonnie Lautenberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Photographer and Writer, Bonnie Lautenberg Designs. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Raymond Debbane founded Invus in1985 and is its President and CEO, based in New York. He also leads the Artal Group. Earlier he was a Boston Consulting Group manager in Paris. He holds an MBA from Stanford, a food science and technology master’s from UC Davis, and agricultural science and engineering degrees from the American University of Beirut. His charity and institutional affiliations are distinct from an institutional cash investment.

Ann Jackson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Rachid Izzar is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Executive Vice President, Global Product Strategy and Commercialization, Biogen, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Adam Hoffman is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Mission Related Investment Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Nancy Goodes is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Former Executive, Nazareth-Century Mills; Secretary, Melvin R. Goodes Family Foundation, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Bonnie Pfeifer Evans is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Senior Sales Associate, Corcoran Group Real Estate; Co-Trustee, The Charles Evans Foundation. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Lanny Edelsohn is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Neurology Professor Emeritus, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Nancy Corzine is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: President and Chief Executive Officer, Nancy Corzine, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Gavin Cook is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Executive Director, Global Alzheimer’s Disease Commercial, Patient Journey and Project Management Head, Eisai US. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Roberta Diaz Brinton is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Scientific Investment Approval Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Carol Seabrook Boulanger is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Randal Sandler is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Vice Chairs group. The foundation lists the outside professional affiliation: Chair, Executive Committee Chair, Compensation Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Thomas F. McWilliams is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Vice Chairs group. The foundation lists the outside professional affiliation: Co-Chair, Mission Related Investment Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Ronald S. Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Chair group. The foundation lists the outside professional affiliation: Chairman, Clinique Laboratories, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Katie Mischik is Chief of Staff and Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Operations + Administration; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Peter Post is listed in Coronet Ventures’ current public directory as Strategic Advisor — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Stephanie Dunphy is Manager, Scientific Operations and Executive Assistant at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Operations + Administration; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Julia Leonard is Manager, Communications at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Communications; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Michael Dooijes is listed in Coronet Ventures’ current public directory as Strategic Advisor — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Emily Berkowitz is Senior Director, Communications at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Communications; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Daniel Gross is Controller at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Marina D'Emic is Chief Financial Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Edward Prunchunas is listed in Coronet Ventures’ current public directory as Board member (Cedars-Sinai Intellectual Property Company board). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Lakita Cavin is Senior Attorney, Mission Related Investments at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

James Laur is listed in Coronet Ventures’ current public directory as Board member (President, Cedars-Sinai Intellectual Property Company). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

David Silver is Senior Director Philanthropy and Partnerships at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Christine Scerra is Senior Director, Special Events and Development Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

David Wrigley is listed in Coronet Ventures’ current public directory as Board member (Cedars-Sinai Health System EVP and CFO). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Allison Ruttley is Major Gifts Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jenna Iachetti is Senior Manager, Special Events at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Koen van Breugel is listed in Coronet Ventures’ current public directory as Investment Director — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Katie Dolan is Senior Manager, External Affairs at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jerica Reeder is Assistant Director, SpeechDx, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Colin Tan is listed in Coronet Ventures’ current public directory as Investment Director and Data Protection Officer — Singapore. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Jennifer Panlilio is Program Officer, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Betsy Mills is Associate Director, Aging and Alzheimer’s Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Alex Chai is listed in Coronet Ventures’ current public directory as Vice President and General Counsel. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Melissa Lee is Director, Diagnostics Accelerator, Digital & AI at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Olga Kahn is Director, Fluid Biomarkers, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jennifer Hsiao-Nakamoto is Senior Program Officer, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Yuko Hara is Director, Aging and Alzheimer’s Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Chandra Gruber is Director, Grants Management at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Marisa Goo is Assistant Director, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jessica Gallegos is Project Manager, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Tyler Demarest is Director, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Kathryn Carnazza is Program Officer, Aging and Alzheimer's Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Aaron Burstein is Head, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Mollie Boettcher is Manager, Grant Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Laura Nisenbaum is Interim Chief Science Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jane McIntosh is Chief Philanthropy and External Affairs Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Karen Harris is Executive Director, Mission Related Investments and Finance at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Isobel Coleman is Chief Executive Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias. Her official biography describes previous McKinsey partnership and twice Senate-confirmed diplomatic service, with a PrincetonBA and OxfordMPhil/DPhil in InternationalRelations.

Phyllis Barkman Ferrell is an ADDF Board of Overseers member, listed as ChiefImpactOfficer for StartUpHealth’s Alzheimer’sMoonshot, SeniorConsultant to GatesVentures and independent adviser at PBFerrell LLC. StartUpHealth’s current own team directory identifies the same full name and original portrait, and her previous role leading external engagement for Alzheimer’s and neurodegeneration at EliLilly. ADDF’s public overseer biography identifies Phyllis Barkman Ferrell as a senior consultant to Gates Ventures LLC alongside her independent consulting business and Alzheimer’s Moonshot work at StartUp Health. This is an external consulting affiliation, rather than an assertion that she is a Gates Ventures employee.

Associate professor at Feinstein’s Institute of Bioelectronic Medicine and leader of the Translational Neurophysiology Laboratory. Studies autonomic neural circuits, immune physiology and therapeutic neuromodulation. Trained in medicine in Thessaloniki and neuroscience/physiology at Washington. Published Northwell affiliation: Associate Professor, Institute of Bioelectronic Medicine, Feinstein Institute for Medical Research.

Chief academic officer directing graduate and medical-student education, faculty development and research administration. SUNY Downstate MD with Boston University internal-medicine training and epidemiology master’s. Published Northwell affiliation: Senior VP & Chief Academic Officer; Betsey Cushing Whitney Professor of Medicine.

Northwell senior vice president and chief marketing and communications officer, responsible for brand, communications and clinical marketing. Also leads Northwell Studios. Published Northwell affiliation: Senior Vice President and Chief Marketing and Communications Officer.

Current Northwell private-equity subcommittee board observer and Huntington Hospital chair emeritus; former system trustee and private-equity subcommittee chair. Founder/managing partner of Northwell Health Equity Partners. Separate external investment-management employment is not treated as Northwell staff or a new fund closing. Published Northwell affiliation: Board Observer, Northwell Private Equity Subcommittee; Chair Emeritus, Huntington Hospital (qualified affiliations).

Current OMVC Associate based in Singapore, leading investment efforts across Southeast Asia and supporting APAC portfolio businesses. Previously worked at Encomenda Capital Partners and studied business at ESADE in Barcelona. Joined the Vectr Fintech Partners platform in2022; its older Vectr directory’s Analyst title remains source-published history, while current OMVC uses Associate.

Published Vectr venture partner with technology, growth-strategy and financial-policy experience. Previously worked in Microsoft advisory services and co-founded open-source intelligence business Xceed Ventures. His biography describes Saudi crowdfunding and open-banking work. Holds a King Saud University computing degree and Harvard general-management training; personal angel investments remain separate.

Chair of Northwell’s board of trustees. Public-health leader and Columbia executive in residence; formerly led JSI, Partnership with Children and AFS-USA. Holds Harvard MBA, Columbia MPH and Princeton BA. Published Northwell affiliation: Chair, Board of Trustees.

Published venture partner of the related Vectr Fintech Partners platform, subsequently OMVC. His biography describes fintech operations work involving WalletConnect, 11:FS and Monzo, following banking and capital-markets advisory work at PwC. No independently verified current bank employment is inferred.

Published Vectr venture partner and media entrepreneur. His biography describes founding roles at 88rising, Stampede Ventures and East West Ventures, plus involvement with Triller and Asian entertainment investments. These undated outside roles are source-published history, and his personal investments are not assigned to Vectr.

Executive vice president and chief operating officer, confirmed by HANYS’ 2026 board announcement. Previously led Northwell’s Western Market. Holds Dartmouth healthcare-delivery science MS, Hofstra MBA and Stony Brook BA. The forum heading says COO while its biographical paragraph retains older COO-elect wording; newer primary evidence resolves the title. Published Northwell affiliation: Executive Vice President and Chief Operating Officer (current 2026 HANYS source).

Published Vectr venture partner with experience expanding Airbnb into Asia and helping launch its Experiences and social-impact initiatives. Previously co-founded restaurant chain Chickenow. This identity is distinct from Vectr co-founder Alan Chan.

Published Vectr venture partner with experience in Israeli technology and international startup partnerships. Founded Upround Ventures and previously worked at theglobe.com; the directory describes advisory work for Nielsen Innovate and interest in digital health. Holds a Kellogg MBA. Undated external affiliations remain source-qualified.

Emergency-medicine chair and Feinstein investigator studying resuscitation, reperfusion and cellular injury. Previously founded resuscitation programmes at Pennsylvania and Chicago; earned his MD at Illinois. Published Northwell affiliation: Chair, Emergency Medicine, Northwell Health; Feinstein Institutes for Medical Research.

Published Vectr operating partner focused on strategy, operations and capital solutions. His career includes Goldman Sachs Asia M&A, strategy leadership at the NBA and NBA China, and senior leadership at Vobile. Holds a Wharton MBA and Washington University undergraduate degree.

Published co-founder and managing partner of Vectr Carbon Partners, with a climate-technology venture-partner affiliation to Vectr. His source biography describes international work in energy, agriculture, waste and technology, and an operating-partner role at Nexus PMG. Studied at Stanford, the University of Pennsylvania and Jochi University. External affiliations are source-published rather than independently recertified for 2026.

Physician-in-chief and Zucker medical-school dean; formerly Northwell chief medical officer. Founding medical-school educator and former vice dean. Published Northwell affiliation: Physician-In-Chief and Dean of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Co-founder and managing partner of Vectr Fintech Partners, subsequently OMVC, with a published Vectr venture-partner affiliation since 2014. Experience includes financial-services technology ventures, acquisitions and government consulting. Holds government and philosophy degrees from William & Mary. Own February 2025 announcement confirms the fintech-platform rebrand; it does not rename all Vectr Ventures.

Co-founder of Vectr Fintech Partners, subsequently OMVC, and a published Vectr venture partner since 2014. Technology entrepreneur and co-author of the securities-crowdfunding framework used in the US JOBS Act. Co-founded Crowdfund Capital Advisors and previously worked in healthcare software. The 2025 OMVC presentation confirms managing-partner status at the related fintech platform.

Current OMVC Principal, confirmed by the manager’s public team page. Leads sourcing, investment diligence, company support, market research, financial analysis and internal technology projects. Before joining the Vectr Fintech Partners platform, he built fintech products at Fidelity Labs. Holds engineering-management and engineering degrees from Dartmouth and a physics degree from Bowdoin. Earlier source-published Vectr analyst and2025 associate titles are historical relative to the current Principal title.

Neurosurgeon and research executive studying neural regulation of immune responses and bioelectronic medicine. Co-founded SetPoint Medical, but this career affiliation alone does not establish a Northwell corporate investment. Holds Boston College chemistry BS and Boston University MD; trained in neurosurgery at New York Hospital–Cornell. Current Northwell and Feinstein roles independently published in his own United Therapeutics board biography. Published Northwell affiliation: Executive Vice President, Research; President and CEO, Feinstein Institutes for Medical Research.

Published Vectr investor-relations associate who joined in 2022. Earlier work includes fund placements, ION Group relationship management and Swire Hotels. Holds a business-administration degree from the University of Edinburgh.

Published finance and operations managing director, overseeing finance, investment diligence and portfolio monitoring. Joined Vectr in 2017 after senior-manager work for private-equity and venture clients at Ernst & Young and accounting firms in New York. Licensed New York CPA.

Joined Northwell in 2021 to lead fixed-wing organ-transplant aviation operations. Aviation executive with an Embry-Riddle degree; this is a qualified subsidiary operational role, not venture investment management. Published Northwell affiliation: Director, Flight Operations, North Shore University Hospital (Northwell subsidiary).

Published product and development managing director, studio co-head and Area28 co-founder. Joined Vectr in 2015 after graphics-engine and product leadership at Bruce Artwick Organization and Microsoft. His biography describes work on games, augmented reality and visualization, plus advising Betatron.

Leads Northwell coordinated acute care, emergency telehealth, patient transfer and EMS medical programmes. Holds Northwestern bachelor’s in cognitive neuroscience and artificial intelligence, SUNY Downstate MD, UCLA emergency training and Hofstra executive MBA. Published Northwell affiliation: Vice President, Transfer and Acute Coordinated Care; Medical Director, Emergency Telehealth Services.

Vectr’s published technology managing director and studio co-head, with responsibility for technology diligence. Joined in 2014 and co-founded Area28 as CTO. Previously a senior computer scientist at Adobe, working on Acrobat and document technology. Berkeley electrical engineering and computer science graduate.

Vectr Ventures co-founder and partner focused on China sourcing and investor relations. Previously a software engineer at IBM Canada and worked in financing and alternative investments at R&F Properties. Studied computer science at the University of Waterloo.

Emergency and aerospace-medicine physician leading Northwell emergency telehealth. Studied at Drake and New York Medical College, trained in North Shore emergency medicine and aerospace medicine at King’s College. Official page caption identifies Bryan McCarty despite the portrait filename spelling Brian McCarthy. Published Northwell affiliation: Physician Lead, Northwell Emergency Telehealth Services; concurrent MDONBOARD Medical Director.

Co-founder and general partner of Vectr Ventures, leading strategy, growth and portfolio support. Also co-founded Vectr Fintech Partners and Hong Kong accelerator Betatron. Holds a business degree from Loyola Marymount and an MBA from the University of San Francisco.

Vectr Ventures co-founder and managing partner responsible for investment strategy. Earlier experience includes Goldman Sachs investment banking, ITC Corporation alternative investments, and founding entertainment-ticketing company iPiao. Duke University graduate.

Joined Holdings in 2023 and oversees MDONBOARD operations. Previously led operations in Northwell clinical departments and women’s health services; holds Dowling MBA and St Joseph’s healthcare-administration bachelor’s. Published Northwell affiliation: Assistant Vice President, Northwell Holdings; concurrent MDONBOARD operations executive.

Leads communications and marketing supporting Holdings’ portfolio and innovation initiatives. Previously worked in academic-healthcare communications at SUNY Downstate; holds a Duquesne business degree. Published Northwell affiliation: Senior Director, Marketing and Communications, Northwell Holdings.

Clinician executive conducting clinical due diligence, supporting venture investments and commercializing clinical innovations. Holds Columbia nursing doctorate and master’s degrees, Cornell science master’s and Rutgers degrees; previously supported Mount Sinai clinical transformation. Published Northwell affiliation: Vice President, Clinical Solutions, Northwell Holdings.

Feng Zhang (WuXi AppTec) is Senior Vice President, API Manufacturing at WuXi AppTec. Over 20 years of experience in API manufacturing. Responsible for the build-up and operations of global API Manufacturing. Bachelor's degree in pharmaceutical from Shanghai Medical University and EMBA degree in Finance and Economics from Shanghai University.

Northwell Holdings managing director overseeing investment strategy, capital investments and portfolio management. Joined Northwell legal affairs in 2016 after M&A/private-equity work at Hughes Hubbard & Reed and Willkie Farr & Gallagher. Holds Duke JD and English MA and Richmond BA. Own 2026 Columbia event post calls her vice president of legal affairs; the 2024 appointment used assistant vice president. Distinct from the existing Cystic Fibrosis Foundation volunteer of the same name. Published Northwell affiliation: Managing Director, Northwell Holdings; Vice President, Legal Affairs (own 2026 event source).

Xiang Wu is Senior Vice President, RCS at WuXi AppTec. Over 20 years of industry experience with proven track record in medicinal chemistry and synthetic organic chemistry. Formerly worked at AMRI. Ph.D. in Medicinal Chemistry from National University of Singapore.

Leads Northwell Holdings’ commercial joint ventures, spinouts and investments; formerly led operations for Northwell Ventures. Joined Northwell in 2015 after health-system, consulting and academic-healthcare leadership. Holds an English bachelor’s from Saint Michael’s and a Columbia MPH. Published Northwell affiliation: President and Chief Executive Officer, Northwell Holdings (corporate venture and innovation arm).

Youchu Wang is Senior Vice President, API Early Phase Development at WuXi AppTec. Over 20 years of experience in synthetic organic chemistry and small molecule process development. Formerly Sr. Scientist of Process Chemistry at Wyeth. Ph.D.in Organic Chemistry from Chinese Academy of Science followed by Postdoctoral Research at Memorial University of Newfoundland, Canada.

Physician executive leading Northwell Health Physician Partners, as stated in his September 22, 2026 American Medical Association interview about physician leadership and care culture. Published Northwell affiliation: Senior Vice President; Executive Director, Northwell Health Physician Partners (September 2026 interview).

Dirk Tormans is Senior Vice President, WuXi Chemistry Global QA at WuXi AppTec. Over 20 years of experience in pharmaceutical quality management, CMC development and commercial manufacturing, regulatory submissions & compliance for small as well as large molecules. Formerly Sr. Director Quality at Johnson & Johnson. Master's degree in Chemical Engineering (microbiology and process technology) from the University of Leuven, Belgium.

Oversees Northwell financial strategy and operations, including reporting, budgeting, cash management, tax, risk and revenue cycle. CPA with Hofstra MBA and BBA; previously worked at Deloitte. Current executive title published by her Big Brothers Big Sisters of Long Island board biography. Published Northwell affiliation: Executive Vice President and Chief Financial Officer.

Leads Northwell’s workforce strategy after joining in 2008. Previously practiced law and management at the New York City Mayor’s Office of Labor Relations. Holds Albany degrees in political science/Africana studies and educational administration, and a JD from New York Law School. Current title corroborated by the National Center for Healthcare Leadership’s April 2026 board publication. Published Northwell affiliation: Senior Vice President and Chief People Officer.

Tao Guo is Senior Vice President, RCS IPM at WuXi AppTec. Over 20 years of experience in drug discovery, recipient of over 40 US issued patents and inventor of one FDA approved drug. Formerly Director of Chemistry at Pharmacopeia and Senior Research Scientist at ARIAD Pharmaceuticals. Ph.D. in Organic Chemistry from Columbia University.

President of Northwell’s Mather Hospital. Previously led strategic alliances and Cohen Children’s Medical Center operations. Holds an MBA from Baruch/Mount Sinai and a health-administration bachelor’s degree from the Medical College of Virginia/Virginia Commonwealth University. Subsidiary hospital leadership is qualified rather than presented as system CEO. Published Northwell affiliation: Senior Vice President; President, Mather Hospital (Northwell subsidiary).

Nursing and health-system leader named executive vice president and president of the Eastern Market in Northwell’s Mather Hospital 2025 community-health assessment, published January 2026. Published Northwell affiliation: Executive Vice President and President, Eastern Market (2025 CHNA published January 2026).

Ke Chen is Senior Vice President, API Late Phase Development and Commercialization at WuXi AppTec. Over 10 years of industry experience with proven track record in Organic Chemistry, small molecule API process R&D and Manufacturing, process technology transfer as well as pharmaceutical CMC development. Formerly Principal Scientist of Process Chemistry at Bristol-Myers Squibb. Ph.D. in Organic Chemistry from University of Rochester.

Physician and public-health leader named as executive vice president of Northwell’s Institute for Community Health and Wellness in Mather Hospital’s 2025 community-health assessment published January 2026. Historical senior-vice-president titles should not replace this later published role. Published Northwell affiliation: Executive Vice President, Institute for Community Health and Wellness (2025 CHNA published January 2026).

Jinling Chen is Senior Vice President, Pharmaceutical Development and Manufacturing at WuXi AppTec. Over 20 years of experience in formulation & process development planning and strategy, drug delivery technologies, formulation, drug product process development and manufacturing, CMC regulatory submission. Holds more than 20 globally recognized patents. Formerly worked at Zeneca, BSM, Lexicon. Ph.D. in Physical Chemistry from Monash University in Australia.

Medical executive responsible for clinical initiatives and patient experience at Northwell’s Katz Institute for Women’s Health, as published in its 2026 Constellation Forum roster. Published Northwell affiliation: Medical Director; Vice President, Clinical Initiatives and Patient Experience, Katz Institute for Women's Health.

Yu Lu is Senior Vice President, WuXi TIDES, WuXi Chemistry Business Operations at WuXi AppTec. Over 20 years of industry experience with a proven track record in pharmaceutical CMC development, business development and marketing, new business creation as well as operations management. Previously worked at Merck and Vertex. Master's degree in chemistry from Duke University and MBA degree from Kellogg School of Management, Northwestern University.

Physician executive leading the Katz Institute for Women’s Health, as named in Northwell’s published 2026 Constellation Forum speaker roster. Published Northwell affiliation: Senior Vice President, Katz Institute for Women's Health.

Cardiologist and medical executive appointed chief medical officer in 2021. Previously led Lenox Hill Hospital after joining Northwell in 2014; earlier practiced at Mount Sinai, NYU and Beth Israel. Completed medical, residency and cardiology training at Mount Sinai. Published Northwell affiliation: Executive Vice President, Chief Medical Officer and Deputy Physician-in-Chief.

Xuanjia Peng is Senior Vice President, WuXi Testing, WuXi Biology, Automation Department at WuXi AppTec. Since joining WuXi AppTec, Dr. Xuanjia Peng has successful track records in leading business and operation units spanning drug discovery hit generation, chemistry catalog, chemistry service operation, and medicinal chemistry service. Ph.D. in Organic Chemistry from Lanzhou University.

Hao Wu is Senior Vice President, Legal Department, Human Resources Department at WuXi AppTec. Over 20 years of rich experience in the fields of legal, compliance management and cross region management in the related areas. Before joining WuXi AppTec, Dr. Wu was General Manager of Legal Department for the China region at Sinar Mas Group – Asia Pulp & Paper, and served as Chief Compliance Counsel for GE Healthcare Greater China region, General Counsel for Momentive Performance Material Asia Pacific region and a practicing lawyer in the US. Dr. Wu received Juris Doctor degree from School of Law of University of the District of Columbia. Also published as Howard Wu; legal April2026 appointment uses Hao Wu, exactmatching career and education.

Pediatric surgical leader and Northwell gun-violence-prevention executive sponsor. Established the Feinstein laboratory studying pediatric injury and inflammation. Studied medicine at Yale and completed surgical training in Pittsburgh. Published Northwell affiliation: Pediatric Surgeon-in-Chief; System Chief, Pediatric Surgery and Acute Care Surgery.

Ming Shi is Senior Vice President, Chief Financial Officer at WuXi AppTec. Over 20 years of rich professional knowledge and management experience in the fields of finance, business development and operations. Most recently worked at General Electric as the Managing Director of Business Development and CFO of GE China. Bachelor degree in International Finance from Shanghai University. Also published as Florence Shi; legal April2026 CFO appointment uses Ming Shi, exactmatching GE China career.

Led Northwell for 23 years before becoming CEO emeritus. His continuing advisory work includes public health, teaching and writing. Earlier served in New York state government, academia and health insurance. This emeritus affiliation supersedes historical CEO labels. Published Northwell affiliation: CEO Emeritus; advisory role (former President and CEO).

Xiaoyong Fu is Executive Vice President, STA at WuXi AppTec. Over 30 years of experience in Organic Chemistry, small molecule API process R&D and Manufacturing, Process technology transfer as well as overall CMC. Formerly Sr. Fellow of Process Chemistry at Schering-Plough/MSD. Ph.D. in Organic Chemistry from University of Wisconsin-Milwaukee.

Richard Connell is US/EU President at WuXi AppTec. Over 35 years of experience in the biotech and drug discovery sector, before joining WuXi AppTec Rick was Vice President of External Research Solutions at Pfizer. Managed a global network of Contract Research Organizations, Contract Manufacturing Organizations, Biotech, technology and academic partnerships. Held multiple management positions in the U.S., UK, Germany and China while at Pfizer and Bayer. Ph.D. in Organic Chemistry from University of Notre Dame.

Emergency physician who became Northwell president and CEO on October 1, 2025. Previously led its central region and emergency-medicine operations; coordinated pandemic operations. Studied medicine at Stony Brook and trained in emergency medicine at Geisinger; served in the US Army Reserve. Published Northwell affiliation: President and Chief Executive Officer (effective October 1, 2025).

Physician and translational scientist with prior protein-therapeutics, gene-therapy and clinical-development leadership at BioMarin, Audentes and Taysha.

Published name: John Bertrand. Founder and CEO of Daupler, a utility-response software company. Existing same-name identities and roles, including the native 8VC adviser, are preserved.

Previously worked at ExxonMobil.

Former founder and CEO of ETIA.

Previously led Total’s petrochemicals business.

Background as a junior project manager and specialisation in international business and management.

Marketing and communications experience with business and consumer brands; works as a consultant.

Works on waste sourcing and strategic partnerships.

Experience following project fabrication and starting up process units.

Holds a PhD in polymer chemistry and has experience in the petrochemical industry.

Background as a lead process engineer in oil and gas.

Experience in pilot operations for polymer production.

Experience in administrative, accounting and human-resources management.

Background in banking in the energy sector and equity research covering oilfield services.

Experienced project director in major oil-and-gas projects.

Process engineer with extensive petrochemistry experience. Axeleo identifies previous leadership of Arkema’s process-safety business unit.

Industrial-technology executive with experience in oil-and-gas licensing sales and leadership of a deep-technology startup. Axeleo identifies prior work at Prosernat and EMEA innovation leadership at Pall Corporation.

Jinling Zhang (张金玲) is CFO and managing partner of Baidu Ventures, as named in its current official directory. Her responsibility combines financial leadership and investment-firm management at the independent AI-focused platform. A current2026SEC issuer biography dates her Baidu Venture CFO/managing-partner tenure to November2020 and describes earlier financial leadership at Baidu Capital, Xiaomi, Cisco and Seagate. Month-only tenure information does not establish a full start date; Baidu Capital is a separate affiliation, not a merged fund manager.

Xue Gao (高雪) is CEO and managing partner of Baidu Ventures, as named in its current official directory. He leads an early-stage investment platform focused on artificial intelligence, robotics, autonomous driving, advanced computing and life sciences. The firm’s official biography and investment commentary emphasize technical innovation and applications in industry, energy, transportation and medicine. His identity is established by the named original firm portrait, rather than unrelated researchers with similar names.

Jill Lopes, CPA, identifies Tiny Orange Capital on her self-published professional profile and describes serving as Director of Finance for a family office, overseeing its financial operations. She is based in the Washington DC–Baltimore area. The exact legal employing vehicle and start date are undisclosed; no independent investment authority or personal checks are inferred.

Sam Stein’s self-published professional profile identifies Tiny Orange Capital and locates him in Washington, DC. It lists James Madison University education and participation in Madison Venture Group and the Financial Management Association. The public profile does not expose his Tiny Orange job title or employment dates; associate or portfolio-company board titles from third-party directories are not asserted.

Tiny Orange Capital’s own public LinkedIn company page lists Kara Olivarria among its affiliated employees, without title or appointment dates. Her self-published profile currently identifies New Way Academy in Phoenix and describes teaching and entrepreneurship interests. The Tiny Orange affiliation is preserved as undated and not asserted to be current investment employment.

Tiny Orange Capital’s own public LinkedIn company page lists Maribeth Bluyus among its affiliated employees, without title or appointment dates. Her newer self-published profile identifies Personal Finance Institute; therefore this is an undated published Tiny Orange association, not a claim of current employment. Her profile describes experience bringing structure, strategy and operational leadership to organizations. Durin’s July18,2025 signed SEC amendment names Maribeth Bluyus its chief executive. This dated legal disclosure follows Mert Sahin’s earlier CEO signature. Exact appointment/end dates and continuing post-acquisition employment are unknown; the May2026 release identifies Steven Verdooner as CEO of the combined NeuroVision business.

Tombot’s SEC-filed September 2022 issuer fundraising exhibit names Ric and Jean Edelman alongside Tiny Orange in its family-office investor section. The display reports USD500,000 for that family-office entry as of September 8, 2022. This is a historical named affiliation, not proof of a current operating position, separate personal check, legal ownership percentage or fund closure. Jean also publishes Self-Care with Jean.

Arlo G. Sorensen is a longtime Whittier-family executive and trustee. Historical SEC disclosures explicitly identify him as co-trustee of seventeen trusts that were members of Whittier Ventures LLC and collectively held a majority of its membership interests, establishing voting and investment control through the trusts. This is a historical control relationship, not a current LLC employment claim or a personal investment. An issuer-published St. Martin Holdings board biography supplies his authentic named portrait and describes his retired presidency and directorship of M.H. Whittier Corporation, Whittier Trust and charitable-board service, and a 1964 accounting bachelor’s from Brigham Young University. Its published board biography identifies St. Martin service since 1998. These separately sourced affiliations do not turn the related companies into the same legal investor.

Liam J. McGuinness is Whittier Trust Company’s chief financial officer, overseeing corporate accounting, tax and client accounting. A 2025 SEC filing also explicitly identifies him as CFO of Whittier Ventures LLC, spelling his surname McGuiness; the native named Whittier Trust biography uses McGuinness and substantiates the shared identity. His LLC affiliation is last-confirmed in that filing, with no exact appointment date inferred. He joined Whittier in 2015 after corporate-finance work at Oaktree Capital Management and financial planning, analysis and systems work at Western Asset Management; earlier employers include IndyMac Bank and Deloitte. He graduated cum laude from Bucknell University with a BSBA and accounting/German double major, and holds CPA and CFA credentials. His native biography also identifies Hillsides treasurer/finance committee service. No personal investment check is inferred.

David A. Dahl is the president and CEO of Whittier Trust Company. The separate Whittier Ventures LLC is a private investment entity: a 2025 SEC filing identifies Dahl as its manager, while historical SEC filings describe him as its president from 1996. These affiliations are dated and do not transfer the trust-company roster or assets to the LLC. His native Whittier Trust biography says he joined in 1993, previously worked as a portfolio manager at Duff & Phelps Investment Management in Chicago, earned a bachelor’s from the University of San Diego and an MBA from the University of Southern California, and holds CFA and CPA credentials. His career includes board service with technology, medical, energy and charitable organizations. Corporate leadership does not imply a personal NeuroVision investment.

David K. Robb was president and chief operating officer of the manager of Gaston Capital Healthcare Fund in its April2017 SEC filing. The portfolio issuer Intezyne’s own board biography describes his earlier economics and asset-allocation work at FirstChicagoInvestmentAdvisors, subsequent futures trading at TheChicagoCorporation, and entrepreneurial experience in technology, manufacturing and medical technology. He also served environmental and animal-welfare nonprofits. This is a historical Gaston affiliation: the current manager directory does not list him, and an undated legacy issuer page is not treated as confirmation of2026 payroll. His identity is distinct from other unrelated people named DavidRobb.

Kyle Radavich joined Gaston Capital as an associate in2024 and was promoted to senior associate on March13,2025, supporting investment sourcing, diligence and portfolio work. Prior positions were at FivePointsCapital and LeerinkPartners. The manager confirms a2020 BBA in finance from UniversityofWisconsinOshkosh and D3 football participation, authenticating his historical university roster photo. His newer own public profile names RoanEquity, so the Gaston website’s retained listing is not represented as verified current employment. Exact departure day remains unknown.

Don (Donald) McCaughey is a current partner at Gaston Capital. The manager’s current biography and own2018 appointment release establish that he joined in2018 after17 years at EatonVance, where he worked as a vice president and regional director. His education is BS ChapmanCollege and MBA PepperdineUniversity. The current site identifies MobilityDesigned board involvement. His career experience raising capital is not the size of a Gaston fund or a personal investment ticket.

Michael K. (Mick) McMahan is the founding partner of Gaston Capital, which he established in2006. The current manager biography describes more than35 years managing portfolios and supporting small businesses, and confirms BA and MPA degrees from the University of North Carolina at ChapelHill. The April2024 management transition expressly preserves his founding-partner role. His manager affiliation and portfolio board positions do not constitute personal cash investments.

Timothy Clackson is a Kesmalea director and former CEO of IDRx and Theseus. He previously led research and development at ARIAD.

Clive Dix chairs Kesmalea. He co-founded Convergence and PowderMed and has worked in pharmacology and pharmaceutical research leadership.

Justin Bower oversees Kesmalea discovery and technology. His background includes medicinal chemistry, Cancer Research UK research leadership and a Loughborough PhD.

Claire Walshe joined Kesmalea in2022. Her earlier research leadership includes Mestag and Topivert; she trained in cancer immunology.

Mark Fox leads Kesmalea finance. He has held financial leadership roles at Quell and Gyroscope and is CIMA qualified.

Harry Finch founded Kesmalea in2020. A medicinal chemist, he previously led chemistry at GlaxoWellcome and co-invented salmeterol.

Robert Johnson leads Kesmalea. His previous roles include CEO of Adrestia, Insmed site leadership and co-founding Affinia and Alacrita.

Ling Hu is identified as chief financial officer and authorised signatory of WI Harper INC VI Management Limited in its April15,2025 SEC ERA Final filing. This is a last-confirmed historical legal-entity capacity; the current WI Harper public operating-team directory does not include her, and current tenure is not independently established. An authentic named portrait has not been located.

Alexander Cheng is an associate in the current WI Harper directory, based in the San Francisco Bay Area. He works on sourcing, diligence, investment and the firm’s digital content, with interests in semiconductors and AI. Earlier he was a user interface designer and product lead at a B2B e-commerce startup. He holds a graphic design degree from the California Institute of the Arts.

Louie Lu is a WI Harper associate in Taipei, focused on advanced materials and industrial technology investments in the United States and Asia Pacific. Before investing he worked in photochemical materials process engineering at GRECO Resin and completed a business development internship at DKSH Taiwan. He holds an MBA from National Chengchi University and a chemical engineering degree from National Taiwan University.

Emily Guo is a senior associate in the current WI Harper directory, working in Shenzhen and Hong Kong. She focuses on technology, robotics, IoT, media and lifestyle businesses. Earlier experience included the firm’s San Francisco office, industrial technology investing at AGIC Capital and an internship at Boston Consulting Group. She studied business administration and digital animation at the University of Southern California.

Eric Fu is a principal in the current WI Harper directory; the individual biography retains an older director title. His expertise covers healthcare services, medical devices, investment and portfolio management. Earlier roles included hospital acquisitions and venture investing at PKU Healthcare, healthcare policy and investment at Taikang, and venture/private equity at Jinmao Capital. He holds a medical master’s degree from Peking University and a business management master’s from Tsinghua.

Harrison Wu is a principal in WI Harper’s Beijing office, focused on information technology, intelligent manufacturing and energy. Before venture investing he worked in business alliances and project management at China Mobile, business development at Hundsun, cloud research at Intel and product management at Shanda. He holds an international MBA associated with MIT Sloan and Tsinghua and a bachelor’s degree from the University of Electronic Science and Technology of China.

Kelvin Sun is a partner in the current WI Harper team directory. His individual biography describes technology investment and operating experience in semiconductors, telecommunications and enterprise IT, with interests in AI, augmented and virtual reality, robotics, blockchain and IoT. He previously led business development and technical marketing and worked at Ericsson on mobile technology. He studied information technology and management information systems at Rensselaer Polytechnic Institute.

Earl Yu is a WI Harper principal investing in healthcare management, robotics, manufacturing, data, enterprise software and AI. Earlier roles included technology, marketing and management at China Unicom, as well as work at Hong Yuan Securities and SDIC Fund. He holds an MBA from Peking University and a bachelor’s degree from Southwestern University of Finance and Economics.

Joyce Lee is a principal in WI Harper’s Taipei office, focused on healthcare, consumer and enterprise technology investments and portfolio support. She previously covered healthcare and finance as an equity analyst at Yuanta and later invested in drug development at Diamond BioFund. She studied political science and economics and earned an MBA in international financial management at National Cheng Kung University. She is distinct from the Uncork Capital finance professional with the same name.

Vincent Gao is a principal at WI Harper and a partner of its Luxin Fund. He focuses on advanced technologies, semiconductors, next-generation information technology and intelligent manufacturing. He joined WI Harper in2014 after investment work at Tuspark and technical management at Cisco. He holds an MBA from Tsinghua University and an engineering degree from Shanghai Jiao Tong University.

Phoebe Wang is a WI Harper partner based in Beijing, focused on advanced technology and new energy. Her biography describes investments in CloudBrain, Neuracle, Airwing and other businesses. Before joining the firm, she worked in product, marketing, online games and publishing strategy at Kingsoft. She holds an MBA from Tsinghua University and an engineering degree from Dalian Maritime University.

Wilson Wu is a managing partner at WI Harper Group. He previously worked in cybersecurity and invests across technology stages. The current primary biography names board responsibilities at Flexcompute, FusionSight, AINekko, RWDC, Alpha Ring and Avaamo. He studied finance, information systems and economics at the University of Virginia, accountancy at Notre Dame, business at Tsinghua and management at MIT. Its USD1.3B AUM statement describes the platform, not a newly closed fund.

Kenneth Teo is listed in EDBI’s current public directory as Senior Principal in International Operations. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Winnie Hsu is a partner in WI Harper’s Taipei office. Her investment interests include communications, wireless technology, digital media, software and technology applications. She also supports portfolio operations and business development. Her current biography identifies portfolio work involving Senhwa, iStaging and Appier among other companies. She holds a finance degree from the University of Adelaide.

Liting Goh is listed in EDBI’s current public directory as Investment Associate in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Edward Liu is published in the current WI Harper directory as managing partner. He supports investment sourcing, seed initiatives, fundraising and portfolio companies, and the individual biography identifies his management of Alibaba Taiwan Entrepreneurs Fund II. Earlier roles included China operations at The Piacente Group, investor relations at Xinhua Sports and Linktone, and venture banking at Silicon Valley Bank. He studied finance and marketing at the University of San Diego and holds an MBA from Shanghai Jiao Tong University.

Sean Peng is a senior partner in WI Harper’s Taipei office, focused on operations, portfolio support and investment opportunities in Taiwan and Beijing. He previously led Greater China investments at H&Q Asia Pacific and held senior roles at Fortune Venture Investment Group. Earlier he worked in engineering and Asian marketing at LSI Logic. He holds an EMBA from Peking University, an MBA from Santa Clara University and an electrical engineering master’s from UT Austin.

Jeremy Tan is listed in EDBI’s current public directory as Investment Associate in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Victor Gan is listed in EDBI’s current public directory as Associate Principal in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Charles Wu is a senior partner at WI Harper, which he joined in2015 after executive and investment leadership at IBM. His earlier roles included vice president and managing director, founding management of the IBM China Investment Fund, and leadership in software and e-business. He studied finance at the University of Houston and completed executive education in venture capital, private equity and joint ventures.

Crystalbel Foo is listed in EDBI’s current public directory as Associate Principal in Fund-of-Funds. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Yigong Wang is WI Harper’s chief operations officer for its Beijing office. He previously spent19 years at China Ocean Shipping Company, serving in research, technology and shipbuilding leadership, and earlier worked at Tianjin University. He holds a mechanical engineering doctorate from Brunel University and a master’s degree in engineering from Tianjin University.

Roy Chua is listed in EDBI’s current public directory as Investment Manager in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Peter Liu, also identified in SEC filings as Pete Yeau-Hwan Liu, is the founder and chairman of WI Harper Group. His career focuses on venture investments across the United States and Asia and building cross-border business relationships. He has supported technology companies through investment, strategic networks and access to Greater China. The current firm biography describes international civic and business affiliations; these relationships are distinct from an investment by their institutions.

Kenny Ng is listed in EDBI’s current public directory as Associate Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jodie Foo is listed in EDBI’s current public directory as Associate Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Nathanael Fheng is listed in EDBI’s current public directory as Principal in Early-stage. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Derrick Xu is listed in EDBI’s current public directory as Investment Manager in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jonathan Trisno is listed in EDBI’s current public directory as Investment Manager in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Siah Sin Cheng is listed in EDBI’s current public directory as Senior Principal in Next Gen Hardware. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tae Yoon Song is listed in EDBI’s current public directory as Investment Associate in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Estella Goh is listed in EDBI’s current public directory as Investment Manager in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Harold Au is listed in EDBI’s current public directory as Senior Principal in Green & Bio Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Christine Giam is EDBI’s Partner leading Green and Bio Economy, Next Generation Hardware, Early-stage and Fund-of-Funds investments. Her current four-sector scope supersedes older archived sector cards. Her biography describes helping build EDB’s New Ventures division, earlier GIC private-equity and Advanced MedTech roles, and biomedical-engineering studies at the National University of Singapore.

Brian Liau is listed in EDBI’s current public directory as Investment Manager in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Andre Lai is listed in EDBI’s current public directory as Investment Manager in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tan Kuan Boone is listed in EDBI’s current public directory as Associate Principal in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Andrew Krishna Ekaputra is listed in EDBI’s current public directory as Senior Principal in Healthcare. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jolene Ooi is EDBI’s Healthcare Partner investing in biotechnology, precision medicine and therapeutic modalities. Her earlier A*STAR research involved gene editing and stem-cell models of Huntington disease. Her qualifications include National University of Singapore life sciences and a Cambridge/Wellcome Sanger molecular-biology doctorate. Published portfolio responsibilities are institutional affiliations rather than personal checks.

Gerald Teng is listed in EDBI’s current public directory as Investment Associate in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Jia Ming Ang is listed in EDBI’s current public directory as Investment Manager in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Michelle Lim is listed in EDBI’s current public directory as Associate Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Tang Chung Hang is listed in EDBI’s current public directory as Senior Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Lim Rong Yang is listed in EDBI’s current public directory as Senior Principal in Digital Economy. EDBI operates as a distinct investment arm of SG Growth Capital. The accessible directory verifies this professional affiliation; no joining date or personal investment is inferred from the role.

Charmaine Kng is EDBI’s Partner for Digital Economy, returning to the firm in mid-2023. Her background includes founding-team work at EvolutionX, DBS venture-debt leadership and earlier EDBI growth-equity investing. EvolutionX is a separate fund, not an EDBI managed vehicle. She holds Nanyang Technological University aerospace-engineering and Imperial College London finance degrees.

Yeung Chia Li is EDBI’s Senior Partner overseeing Digital Economy investments. His published biography describes ICT and fund-of-funds investing, market expansion and portfolio value creation. Earlier experience includes Motorola hardware and RF engineering; his qualifications include Nanyang Technological University engineering and a National University of Singapore MBA.

Paul Ng is EDBI’s Chief Executive Officer, appointed on 1 February 2023, and SG Growth Capital’s Chief Corporate Officer. The government directory identifies him as Paul Ng Tat Peng. He joined EDBI in 2010, following investment work at GIC and IT infrastructure work at PSA. He holds a CFA charter, a Singapore Management University wealth-management master’s degree and a National University of Singapore electrical-engineering degree. SGGC parent CEO Choo Heng Tong holds a separate role.

Hugh Chen holds the source-published role of Associate within RA Capital Management’s Healthcare group. The individual directory reports joining in2026; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: UC San Diego, Harvard University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.